Silvan Tuerkcan
Stock Analyst at Citizens
(4.41)
# 313
Out of 5,239 analysts
161
Total ratings
48.28%
Success rate
22.12%
Average return
Main Sectors:
Stocks Rated by Silvan Tuerkcan
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| CRSP CRISPR Therapeutics AG | Reiterates: Market Outperform | $86 | $52.83 | +62.79% | 17 | Dec 23, 2025 | |
| NUVB Nuvation Bio | Maintains: Market Outperform | $8 → $10 | $4.84 | +106.61% | 5 | Nov 20, 2025 | |
| ENGN enGene Therapeutics | Maintains: Market Outperform | $18 → $21 | $1.44 | +1,358.33% | 5 | Nov 12, 2025 | |
| NTLA Intellia Therapeutics | Maintains: Market Outperform | $29 → $21 | $13.99 | +50.11% | 14 | Nov 7, 2025 | |
| TSHA Taysha Gene Therapies | Maintains: Market Outperform | $6 → $8 | $6.85 | +16.79% | 14 | Nov 5, 2025 | |
| BNTC Benitec Biopharma | Maintains: Market Outperform | $20 → $22 | $11.84 | +85.81% | 14 | Nov 4, 2025 | |
| JSPR Jasper Therapeutics | Maintains: Market Outperform | $12 → $6 | $0.91 | +557.53% | 7 | Sep 22, 2025 | |
| PHR Phreesia | Maintains: Market Outperform | $30 → $34 | $9.61 | +253.80% | 1 | Sep 8, 2025 | |
| IDYA IDEAYA Biosciences | Maintains: Market Outperform | $41 → $45 | $28.12 | +60.03% | 2 | Sep 8, 2025 | |
| EXEL Exelixis | Reiterates: Market Outperform | $50 | $49.46 | +1.09% | 23 | Jul 29, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Market Outperform | $15 | $7.72 | +94.30% | 3 | Jun 6, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Outperform | $10 → $6 | $3.30 | +81.82% | 3 | May 20, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Market Outperform | $9 | $4.24 | +112.26% | 3 | May 15, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | $120 | $16.47 | +628.60% | 12 | May 9, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Market Outperform | $17 | $1.89 | +799.47% | 5 | Mar 26, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Market Outperform | $4 | $2.48 | +61.29% | 1 | Jan 8, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Market Outperform | $21 | $12.93 | +62.41% | 10 | Dec 12, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | n/a | $3.52 | - | 12 | Nov 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Market Outperform | $6 | $4.00 | +50.00% | 6 | May 31, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $240 → $280 | $71.99 | +288.94% | 3 | Mar 5, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Outperform | $18 → $18 | $12.66 | +42.18% | 1 | Jan 26, 2023 |
CRISPR Therapeutics AG
Dec 23, 2025
Reiterates: Market Outperform
Price Target: $86
Current: $52.83
Upside: +62.79%
Nuvation Bio
Nov 20, 2025
Maintains: Market Outperform
Price Target: $8 → $10
Current: $4.84
Upside: +106.61%
enGene Therapeutics
Nov 12, 2025
Maintains: Market Outperform
Price Target: $18 → $21
Current: $1.44
Upside: +1,358.33%
Intellia Therapeutics
Nov 7, 2025
Maintains: Market Outperform
Price Target: $29 → $21
Current: $13.99
Upside: +50.11%
Taysha Gene Therapies
Nov 5, 2025
Maintains: Market Outperform
Price Target: $6 → $8
Current: $6.85
Upside: +16.79%
Benitec Biopharma
Nov 4, 2025
Maintains: Market Outperform
Price Target: $20 → $22
Current: $11.84
Upside: +85.81%
Jasper Therapeutics
Sep 22, 2025
Maintains: Market Outperform
Price Target: $12 → $6
Current: $0.91
Upside: +557.53%
Phreesia
Sep 8, 2025
Maintains: Market Outperform
Price Target: $30 → $34
Current: $9.61
Upside: +253.80%
IDEAYA Biosciences
Sep 8, 2025
Maintains: Market Outperform
Price Target: $41 → $45
Current: $28.12
Upside: +60.03%
Exelixis
Jul 29, 2025
Reiterates: Market Outperform
Price Target: $50
Current: $49.46
Upside: +1.09%
Jun 6, 2025
Reiterates: Market Outperform
Price Target: $15
Current: $7.72
Upside: +94.30%
May 20, 2025
Maintains: Market Outperform
Price Target: $10 → $6
Current: $3.30
Upside: +81.82%
May 15, 2025
Reiterates: Market Outperform
Price Target: $9
Current: $4.24
Upside: +112.26%
May 9, 2025
Downgrades: Market Perform
Price Target: $120
Current: $16.47
Upside: +628.60%
Mar 26, 2025
Reiterates: Market Outperform
Price Target: $17
Current: $1.89
Upside: +799.47%
Jan 8, 2025
Initiates: Market Outperform
Price Target: $4
Current: $2.48
Upside: +61.29%
Dec 12, 2024
Reiterates: Market Outperform
Price Target: $21
Current: $12.93
Upside: +62.41%
Nov 7, 2024
Downgrades: Market Perform
Price Target: n/a
Current: $3.52
Upside: -
May 31, 2024
Reiterates: Market Outperform
Price Target: $6
Current: $4.00
Upside: +50.00%
Mar 5, 2024
Maintains: Buy
Price Target: $240 → $280
Current: $71.99
Upside: +288.94%
Jan 26, 2023
Maintains: Market Outperform
Price Target: $18 → $18
Current: $12.66
Upside: +42.18%